(Sharecast News) - Arecor Therapeutics updated the market on an announcement made by its subsidiary Tetris Pharma on Thursday, regarding the launch of the 'Ogluo' glucagon prefilled autoinjector pen in the Netherlands.
The AIM-traded firm said the launch was a significant advancement in providing treatment for severe hypoglycaemia in individuals aged two years and above living with diabetes mellitus.
It said the product was being introduced to the Dutch market through Goodlife, under its pre-existing commercialisation agreement with Tetris Pharma.
The agreement designated Goodlife as the exclusive partner responsible for the importation, marketing and distribution of Ogluo in the Belgium, Netherlands and Luxembourg (Benelux) region.
"The launch of Ogluo in the Netherlands presents a significant milestone for Tetris Pharma, strengthening the commercial reach and pan-European presence of this important product and giving patients living with diabetes who may experience severe hypoglycaemia, a treatment option to tackle those events," said Tetris Pharma's senior vice-president and commercial and general manager Dr Helen Parris.
"Goodlife's leading know-how and expertise of regional market dynamics make them an ideal partner to support with the roll-out of Ogluo in the BeNeLux region.
"We look forward to continuing to expand our reach within Europe to bring this treatment option to people living with diabetes."
At 0849 GMT, shares in Arecor Therapeutics were up 1.6% at 139.7p.
Reporting by Josh White for Sharecast.com.
Arecor Therape (AREC)